Kynmobi

Mobility decreased, Parkinson's Disease

Treatment

3 FDA approvals

20 Active Studies for Kynmobi

Treatment for

Mobility decreased

What is Kynmobi

ApomorphineThe Generic name of this drug

Treatment SummaryApomorphine is a drug used to treat the lack of movement associated with Parkinson’s disease. It was first created in 1845 and first used to treat Parkinson’s in 1884. Apomorphine has also been studied as a potential treatment for other conditions, such as vomiting, alcoholism, and other movement disorders. The medication received FDA approval in 2004.

Apokynis the brand name

image of different drug pills on a surface

Kynmobi Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Apokyn

Apomorphine

2004

Approved as Treatment by the FDA

Apomorphine, otherwise called Apokyn, is approved by the FDA for 3 uses including Parkinson's Disease (PD) and Mobility decreased .

Parkinson's Disease (PD)

Mobility decreased

Parkinson's Disease

Effectiveness

How Kynmobi Affects PatientsApomorphine is a drug that affects the brain and can help with motor control. It has a short-term effect and not much of the drug is needed for it to be effective. However, patients should be aware of potential side effects, such as nausea and vomiting, feeling sleepy during the day, low blood pressure, mouth irritation, falling, hallucinations, acting in an aggressive or impulsive way, feeling very hot, and an increased risk of heart problems. Taking an anti-nausea medicine called trimethobenzamide before or while taking apomorphine can help reduce these side effects. It is generally recommended to take this

How Kynmobi works in the bodyApomorphine is a drug that binds to dopamine receptors in the brain, which can help with the movement difficulties associated with Parkinson's disease. We don't know exactly how it works, but it appears to have an effect on a specific part of the brain responsible for movement control.

When to interrupt dosage

The prescribed dosage of Kynmobi is dependent on the specified ailment. The amount of dosage also varies as per the delivery technique (e.g. Kit - Sublingual or Liquid - Subcutaneous) outlined in the table beneath.

Condition

Dosage

Administration

Parkinson's Disease

, 30.0 mg/mL, 10.0 mg, 10.0 mg/mL, 15.0 mg, 25.0 mg, 30.0 mg, 20.0 mg

, Subcutaneous, Injection, Injection - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Film, soluble, Kit - Sublingual, Sublingual, Film, soluble - Sublingual, Kit

Mobility decreased

, 30.0 mg/mL, 10.0 mg, 10.0 mg/mL, 15.0 mg, 25.0 mg, 30.0 mg, 20.0 mg

, Subcutaneous, Injection, Injection - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Film, soluble, Kit - Sublingual, Sublingual, Film, soluble - Sublingual, Kit

Warnings

Kynmobi Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Kynmobi.

Common Kynmobi Drug Interactions

Drug Name

Risk Level

Description

Amiodarone

Major

The metabolism of Amiodarone can be decreased when combined with Apomorphine.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Apomorphine.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Apomorphine.

Azelastine

Major

Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Apomorphine.

Kynmobi Toxicity & Overdose RiskThose who overdose on apomorphine may experience nausea, low blood pressure, and even loss of consciousness. Treatment of overdose should involve supportive care and measures to alleviate symptoms. The toxic dose of apomorphine in mice has been found to be 145µg/kg.

image of a doctor in a lab doing drug, clinical research

Kynmobi Novel Uses: Which Conditions Have a Clinical Trial Featuring Kynmobi?

45 active trials are in process to investigate the potential of Kynmobi in alleviating symptoms of Parkinson's Disease.

Condition

Clinical Trials

Trial Phases

Parkinson's Disease

39 Actively Recruiting

Not Applicable, Phase 1, Phase 4, Phase 2, Phase 3, Early Phase 1

Mobility decreased

0 Actively Recruiting

Kynmobi Reviews: What are patients saying about Kynmobi?

4.3Patient Review

5/31/2021

Kynmobi for Parkinson's Disease

This drug is very effective in getting my mom unstuck, but unfortunately it comes with the side effect of nausea. We've found that ginger chews help a bit, but ultimately the decision to take this medication or not is a tough one.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about kynmobi

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Kynmobi a controlled substance?

"Kynmobi is not a controlled substance like morphine and therefore does not have a risk of abuse or dependence."

Answered by AI

When was Kynmobi FDA approved?

"The FDA approved KYNMOBI for the treatment of short-term, intermittent OFF episodes in people with Parkinson's disease in May 2020. Jun 22, 2020"

Answered by AI

What are the side effects of Kynmobi?

"The following effects may occur: nausea, vomiting, mouth pain/sores/numbness, gum swelling, dry mouth, headache, dizziness, drowsiness, tiredness, or runny nose. If you experience any of these effects, tell your doctor or pharmacist."

Answered by AI

What is Kynmobi used for?

"Kynmobi is a medication that works by mimicking the brain chemical dopamine. It is meant to be used to help with "off" time in Parkinson's, which is when symptoms get worse. It can be used up to 5 times per day, in addition to other Parkinson's medications."

Answered by AI